Yahoo Finance

Agenus Up on Positive Prophage Data

Prophage is being developed for the treatment of patients with newly diagnosed glioblastoma multiforme (GBM.V). Results from the study revealed that the median overall survival of approximately 24 ...
NBC News

Data From Prophage Phase 2 Glioma Trial to be Presented at the American Society of Clinical Oncology (ASCO) 2011 Annual Meeting

LEXINGTON, Mass., April 6, 2011 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN) announced today that new data from a Phase 2 trial testing the Prophage G-200 vaccine (HSPPC-96; vitespen) in recurrent ...
Yahoo Finance

Agenus, NCI Ink Deal to Evaluate Prophage-Keytruda Combo

Agenus Inc. AGEN announced that it has entered into a clinical trial collaboration with the National Cancer Institute (NCI) to evaluate its personalized autologous vaccine candidate, Prophage ...
NBC News

New Data From Prophage G-200 Phase 2 Recurrent Glioma Trial to be Presented at the American Society of Clinical Oncology (ASCO) 2011 Annual Meeting

LEXINGTON, Mass., May 18, 2011 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN) today announced that new data from a Phase 2 trial testing the Prophage G-200 vaccine (HSPPC-96; vitespen) in recurrent ...